ACRS Aclaris Therapeutics, Inc.

24.32
-0.49  -2%
Previous Close 24.81
Open 24.86
Price To book 4.04
Market Cap 650.15M
Shares 26,733,000
Volume 294,405
Short Ratio 6.90
Av. Daily Volume 276,327

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated 2H 2017.
ATI-50002
Patchy alopecia areata
Phase 2 trial to be initiated 2H 2017.
ATI-50001
Alopecia totalis and alopecia universalis
PDUFA date is December 24, 2017
A-101
Seborrheic keratosis (SK)
Phase 2 data released August 2016. Plans to initiate two Phase 2 trials in mid-2017.
A-101
Common warts (verruca vulgaris)

Latest News

  1. Aclaris reports 1Q loss
  2. Aclaris Therapeutics to Announce First Quarter 2017 Financial Results on May 9, 2017
  3. FDA Accepts Aclaris Therapeutics’ New Drug Application for Topical Treatment of Seborrheic Keratosis, a Common Skin Condition
  4. Aclaris Therapeutics Reports First Quarter 2017 Financial Results
  5. Investor Network: Aclaris Therapeutics, Inc. to Host Earnings Call
  6. Aclaris Therapeutics Completes Phase 1 Clinical Trial of ATI-50001 for the Treatment of Alopecia Universalis and Alopecia Totalis
  7. Aclaris Therapeutics to Attend Upcoming Investor Conferences
  8. Aclaris Therapeutics Announces Notice of Allowance for a U.S. Patent Application Covering Lead Candidate A-101 Topical Solution
  9. Aclaris Therapeutics Hosts Symposium on JAK Inhibitors at the 76th Annual Society for Investigative Dermatology Meeting
  10. Aclaris Therapeutics Announces Notice of Allowance for Two U.S. Patent Applications Covering Baricitnib and Decernotinib, Respectively, for Hair Loss Disorders
  11. Edited Transcript of ACRS earnings conference call or presentation 15-Mar-17 12:00pm GMT
  12. Aclaris Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
  13. Aclaris Therapeutics Submits New Drug Application for A-101 as a Novel Treatment for Seborrheic Keratosis – a Common Skin Condition
  14. Aclaris Therapeutics (ACRS) Worth a Look: Stock Rises 8.5%
  15. Aclaris Therapeutics to Announce Fourth Quarter and Full Year 2016 Financial Results on March 15, 2017
  16. Skin Lesion Drug Only Scratches the Surface, Says Aclaris CEO